Edoxaban versus Warfarin in Patients with Atrial Fibrillation

Cited by (1,005)

Items 101–200 of 1,005

1. Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society
   Cecilia Marianne Linde, Maria Grazia Bongiorni, Ulrika Maria Birgersdotter-Green, Anne B. Curtis, Isabel Deisenhofer, Tetsushi Furokawa, Anne M. Gillis, Kristina Hermann Haugaa, Gregory Y.H. Lip, Isabelle C. Van Gelder et al. · 2018 · EP Europace
2. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial
   Erin Ann Bohula, Robert Patrick Giugliano, Christian Thomas Ruff, Julia Kuder, Sabina A. Murphy, Elliott Marshall Antman, Eugene Braunwald · 2016 · Circulation
3. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial
   Renato D. Lópes, Marco Alings, Stuart J. Connolly, Heather Beresh, Christopher Bull Granger, Juan Benezet Mazuecos, Giuseppe Boriani, Jens Cosedis Nielsen, David Conen, Stefan Hans Hohnloser et al. · 2017 · American Heart Journal
4. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
   Mintu P. Turakhia, Peter J. Blankestijn, Juan Jesús Carrero, Catherine M. Clase, Rajat Deo, Charles A. Herzog, Scott Eric Kasner, ROD S. PASSMAN, Roberto Pecoits‐Filho, Holger Reinecke et al. · 2018 · European Heart Journal
5. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve
   Hélio Penna Guimarães, Renato D. Lópes, Pedro Gabriel Melo de Barros e Silva, Idelzuita Leandro Liporace, Roney Orismar Sampaio, Flávio Tarasoutchi, Conrado Roberto Hoffmann Filho, Rodrigo de Lemos Soares Patriota, Tiago Luiz Luz Leiria, Diana Lamprea et al. · 2020 · New England Journal of Medicine
6. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial
   Eri Toda Kato, Robert Patrick Giugliano, Christian Thomas Ruff, Yukihiro Koretsune, Takeshi Yamashita, Róbert Gábor Kiss, Francesco Nordio, Sabina A. Murphy, Tetsuya Kimura, James Jin et al. · 2016 · Journal of the American Heart Association
7. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments
   Jessica L. Mega, Tabassome Simon · 2015 · The Lancet
8. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study
   Jeff S. Healey, Jonas Oldgren, Michael D. Ezekowitz, Jun Zhu, Prem Pais, Jia Wang, Patrick Commerford, Petr Janský, Álvaro Avezum, Alben Sigamani et al. · 2016 · The Lancet
9. The Changing Landscape for Stroke Prevention in AF
   Menno Volkert Huisman, Kenneth Jay Rothman, Miney Paquette, Christine Teutsch, Hans‐Christoph Diener, Sérgio Dubner, Jonathan L. Halperin, Chang Sheng, Kristina Zint, Amelie Elsaesser et al. · 2017 · Journal of the American College of Cardiology
10. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR
    Nicolas M. Van Mieghem, Martin Unverdorben, Christian Hengstenberg, Helge Möllmann, Roxana Mehran, Diego López‐Otero, Luis Nombela-Franco y, Raul Moreno, Peter Nordbeck, Holger Thiele et al. · 2021 · New England Journal of Medicine
11. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation
    Laurent Macle, John A. Cairns, Kori Leblanc, Teresa S.M. Tsang, Allan Cameron Skanes, Jafna L. Cox, Jeff S. Healey, Alan Bell, Louise Pilote, Jason G. Andrade et al. · 2016 · Canadian Journal of Cardiology
12. 2020 ACC/AHA guideline for the management of patients with valvular heart disease
    Otto, Catherine M., Nishimura, Rick A., Bonow, Robert O., Carabello, Blase A., Erwin, John P., Gentile, Federico, Jneid, Hani, Krieger, Eric V., Mack, Michael, McLeod, Christopher et al. · 2021 · The Journal of Thoracic and Cardiovascular Surgery
13. Left Ventricular Thrombus After Acute Myocardial Infarction
    Cian P. McCarthy, Muthiah Vaduganathan, Killian J. McCarthy, James L. Januzzi, Deepak L. Bhatt, John William McEvoy · 2018 · JAMA Cardiology
14. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)
    Gregory Y.H. Lip, J.P. Collet, Michael Haude, Robert Byrne, Eugene H. Chung, Laurent Fauchier, Sigrun Halvorsen, Dennis H. Lau, Néstor López-Cabanillas, Maddalena Lettino et al. · 2018 · EP Europace
15. Causes of Death in Anticoagulated Patients With Atrial Fibrillation
    Antonio Gómez‐Outes, Julián Lagunar-Ruíz, Ana‐Isabel Terleira‐Fernández, Gonzalo Calvo, Maria Luisa Suárez-Gea, Emilio Vargas · 2016 · Journal of the American College of Cardiology
16. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013):– Digest Version –
    JCSJointWorkingGroup · 2014 · Circulation
17. Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation
    Aya Fukuma Ozaki, A. Choi, Quan T. Le, Dennis T. Ko, Janet K. Han, Sandy S. Park, Cynthia Anne Jackevicius · 2020 · Circulation Cardiovascular Quality and Outcomes
18. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?
    Chao, Tze-Fan, Liu, Chia-Jen, Wang, Kang-Ling, Lin, Yenn-Jiang, Chang, Shih-Lin, Lo, Li-Wei, Hu, Yu-Feng, Tuan, Ta-Chuan, Chen, Tzeng-Ji, Lip, Gregory Y.H. et al. · 2015 · Journal of the American College of Cardiology
19. Hypertension and Atrial Fibrillation
    Paolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi · 2018 · Circulation Research
20. Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate
    Hamim Zahir, Karen S Brown, Alexander G. Vandell, Madhuri Desai, Jen‐Fue Maa, Victor Dishy, Barbara Lomeli, Annette Feussner, Wenqin Feng, Ling He et al. · 2014 · Circulation
21. Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association
    Amish N. Raval, Joaquin E. Cigarroa, Mina K. Chung, Larry J. Díaz‐Sandoval, Deborah Diercks, Jonathan Paul Piccini, Hee Soo Jung, Jeffrey B. Washam, Babu Guai Welch, Allyson R. Zazulia et al. · 2017 · Circulation
22. Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial
    Andreas Goette, José Luís Merino, Michael D. Ezekowitz, Dmitry Zamoryakhin, Michael R. Melino, James Jin, Michele F. Mercuri, MICHAEL A. GROSSO, Victor Serrano-Fernandez, Naab Al‐Saady et al. · 2016 · The Lancet
23. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation
    Xiaoxi Yao, Navdeep Tangri, Bernard John Gersh, Lindsey R. Sangaralingham, Nilay D. Shah, Karl A. Nath, Peter A. Noseworthy · 2017 · Journal of the American College of Cardiology
24. Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials
    William F. McIntyre, Alexander Philipp Benz, Nina Becher, Jeff S. Healey, Christopher Bull Granger, Léna Rivard, A. John Camm, Andreas Goette, Antonia Zapf, Marco Alings et al. · 2023 · Circulation
25. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary
    Jan Steffel, Peter B. Verhamme, Tatjana Potpara, Pierre Albaladejo, Matthias Antz, Lien Desteghe, Karl Georg Hæusler, Jonas Oldgren, Holger Reinecke, Vanessa Roldán et al. · 2018 · EP Europace
26. Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi
    Austin A. Robinson, Cory Ross Trankle, Grayson C. Eubanks, Christopher L. Schumann, Paul Thompson, Ryan L. Wallace, Shouri Gottiparthi, Benjamin K. Ruth, Christopher M. Kramer, Michael Salerno et al. · 2020 · JAMA Cardiology
27. Atrial Fibrillation
    PETER J. ZIMETBAUM · 2017 · Annals of Internal Medicine
28. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism
    Manuj Sharma, Victoria R. Cornelius, Jignesh Prakash Patel, Graham Davies, Mariam Molokhia · 2015 · Circulation
29. PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease
    Paul Khairy, George F. Van Hare, Seshadri Balaji, Charles I. Berul, Frank Cecchin, Mitchell I. Cohen, Curt J. Daniels, Barbara J. Deal, Joseph A. Dearani, Natasja M. S. de Groot et al. · 2014 · Canadian Journal of Cardiology
30. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease
    Álvaro Avezum, Renato D. Lópes, Phillip J. Schulte, Fernando Tomas Lanas, Bernard John Gersh, Michael Hanna, Prem Pais, Çetin Erol, Rafael Díaz, Maria Cecilia Bahit et al. · 2015 · Circulation
31. 2020 Clinical practice guidelines for Stable coronary artery disease
    Russian Society of Cardiology · 2020 · Russian Journal of Cardiology
32. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis
    Felicita Andreotti, Bianca Rocca, Steen Husted, Ramzi Ajjan, Jurriën M. ten Berg, Marco Cattaneo, Jean‐Philippe Collet, Raffaele De Caterina, Keith A.A. Fox, Sigrun Halvorsen et al. · 2015 · European Heart Journal
33. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation
    David Julian Seiffge, David John Werring, Maurizio Paciaroni, Jesse Dawson, Steven J. Warach, Truman John Milling, Stefan T. Engelter, Urs Fischer, Bo G Norrving · 2018 · The Lancet Neurology
34. Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry
    Sean D. Pokorney, DaJuanicia N. Simon, Laine Elliott Thomas, Gregg C. Fonarow, Peter Russell Kowey, Paul Chang, Daniel E. Singer, Jack Ansell, Rosalia G Blanco, Bernard John Gersh et al. · 2015 · American Heart Journal
35. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation
    Peter A. Noseworthy, Xiaoxi Yao, Neena S. Abraham, Lindsey R. Sangaralingham, Robert D. McBane, Nilay D. Shah · 2016 · CHEST Journal
36. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
    Dominick Joseph Angiolillo, Shaun G. Goodman, Deepak L. Bhatt, John W. Eikelboom, Matthew J. Price, David J. Moliterno, Christopher Paul Cannon, Jean‐François Tanguay, Christopher Bull Granger, Laura Mauri et al. · 2018 · Circulation
37. Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation
    Kang-Ling Wang, Gregory Y.H. Lip, Shing‐Jong Lin, Chern‐En Chiang · 2015 · Stroke
38. Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality
    Taku Inohara, Ying Xian, Li Liang, Roland Matsouaka, Jeffrey L. Saver, Eric Edward Smith, Lee H. Schwamm, Mathew J. Reeves, Adrian F. Hernandez, Deepak L. Bhatt et al. · 2018 · JAMA
39. 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation
    Jason G. Andrade, Atul Verma, L. Brent Mitchell, Ratika Parkash, Kori Leblanc, Clare L. Atzema, Jeff S. Healey, Alan Bell, John A. Cairns, Stuart J. Connolly et al. · 2018 · Canadian Journal of Cardiology
40. STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management
    Pierre R. Tibi, Robert Scott McClure, Jiapeng Huang, Robert A. Baker, David Fitzgerald, C. David Mazer, Marc E. Stone, Danny Chu, Alfred H. Stammers, Tim Dickinson et al. · 2021 · The Annals of Thoracic Surgery
41. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure
    Jeff S. Healey, Martina Brueckmann, John W. Eikelboom, Michael D. Ezekowitz, Mandy Fraessdorf, Herbert Noack, Jonas Oldgren, Paul A. Reilly, Alex C. Spyropoulos, Lars C. Wallentin et al. · 2014 · Thrombosis and Haemostasis
42. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
    Dolly A. Parasrampuria, Kenneth E. Truitt · 2015 · Clinical Pharmacokinetics
43. Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010–2017
    Junya Zhu, G. Caleb Alexander, Saman Nazarian, Jodi B Segal, Albert W. Wu · 2018 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
44. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non–vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6) trial
    Paulus F. Kirchhof, Benjamin F. Blank, Melanie Calvert, A. John Camm, GREGORY I. CHLOUVERAKIS, Hans‐Christoph Diener, Andreas Goette, Andrea Huening, Gregory Y.H. Lip, EMMANUEL N. SIMANTIRAKIS et al. · 2017 · American Heart Journal
45. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter
    M. S. Arakelyan, Leo A. Bockeria, Elena Vasilieva, Golitsyn Sp, Elena Zelikovna Golukhova, M. V. Gorev, Karapet V. Davtyan, Oksana M. Drapkina, Кропачева Екатерина Станиславовна, Е. А. Kuchinskaya et al. · 2021 · Russian Journal of Cardiology
46. Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF
    Kevin E. Chan, Robert Patrick Giugliano, Manesh R. Patel, Stuart Abramson, Meg Jardine, Sophia J. Zhao, Vlado Perkovic, Franklin W. Maddux, Jonathan Paul Piccini · 2016 · Journal of the American College of Cardiology
47. Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation
    Ying Xian, Emily Claire O'Brien, Li Liang, Haolin Xu, Lee H. Schwamm, Gregg C. Fonarow, Deepak L. Bhatt, Eric Edward Smith, DaiWai M. Olson, Lesley Maisch et al. · 2017 · JAMA
48. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines
    Andrew Veitch, Geoffroy Vanbiervliet, Anthony Gershlick, Christian Boustière, Trevor P Baglin, Lesley‐Ann Smith, Franco Radaelli, Evelyn Knight, Ian Mark Gralnek, Cesare Hassan et al. · 2016 · Endoscopy
49. Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)
    Gregory Y.H. Lip, António Coca, Thomas Kahan, Giuseppe Boriani, Antonis S. Manolis, Michael Hecht Olsen, Ali̇ Oto, Tatjana Potpara, Jan Steffel, Francisco R. Marín et al. · 2017 · EP Europace
50. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study
    Peter L. Gross, Bruce C. Ritchie, Susan Nahirniak, Yulia Lin, Lani Lieberman, Marc Carrier, Mark Andrew Crowther, Indy Ghosh, Alejandro Lazo‐Langner, Michelle Zondag et al. · 2018 · Thrombosis and Haemostasis
51. Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology
    Massimo Francesco Piepoli, Ana Abreu, Christian Albus, Marco Ambrosetti, Carlos Brotons, Alberico Luigi Catapano, Ugo Corrà, Bernard Cosyns, Christi Deaton, Ian M Graham et al. · 2019 · European Journal of Preventive Cardiology
52. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries
    Benjamin Adam Steinberg, Haiyan Gao, Peter Shrader, Karen Pieper, Laine Elliott Thomas, A. John Camm, Michael D. Ezekowitz, Gregg C. Fonarow, Bernard John Gersh, Samuel Zachary Goldhaber et al. · 2017 · American Heart Journal
53. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies
    Apostolos Tzikas, David R. Holmes, Sameer A. Gafoor, Carlos Eduardo Ruiz, Carina Blomström‐Lundqvist, Hans‐Christoph Diener, Riccardo Cappato, Saibal Kar, Randal J. Lee, Robert A. Byrne et al. · 2016 · EP Europace
54. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation
    George Ntaios, Vasileios Papavasileiou, Konstantinos P. Makaritsis, Konstantinos N. Vemmos, Patrik Michel, Gregory Y.H. Lip · 2017 · Stroke
55. Fibrotic Atrial Cardiomyopathy, Atrial Fibrillation, and Thromboembolism
    Benjamin J. Hirsh, Robert S. Copeland-Halperin, Jonathan L. Halperin · 2015 · Journal of the American College of Cardiology
56. Comorbidity of atrial fibrillation and heart failure
    Liang‐Han Ling, Peter M. Kistler, Jonathan M. Kalman, RICHARD JOHN SCHILLING, Ross Jacob Hunter · 2015 · Nature Reviews Cardiology
57. Early Safety and Efficacy of Percutaneous Left Atrial Appendage Suture Ligation
    Matthew J. Price, Douglas N Gibson, Steven Joseph Yakubov, Jason C. Schultz, Luigi Di Biase, Andrea Natale, J. David Burkhardt, Ashish Pershad, Timothy Byrne, Brett Gidney et al. · 2014 · Journal of the American College of Cardiology
58. Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation
    Yukiko Matsumura‐Nakano, Satoshi Shizuta, Akihiro Komasa, Takeshi Morimoto, Hisaki Masuda, Hiroki Shiomi, Koji Goto, Kentaro Nakai, Hisashi Ogawa, Atsushi Kobori et al. · 2019 · Circulation
59. 2024 Clinical practice guidelines for Chronic heart failure
    Albert S. Galyavich, Sergey N. Tereshchenko, T. M. Uskach, Fail T. Ageev, D. M. Aronov, G. P. Arutyunov, Yu. L. Begrambekova, Yu. N. Belenkov, Sergey Anatol'evich Boytsov, Marina Gennad'evna Bubnova et al. · 2024 · Russian Journal of Cardiology
60. Patent foramen ovale
    Shunichi Homma, Steven Russell Messe, Tatjana Rundek, Yee‐Ping Sun, Jennifer Franke, Karina W. Davidson, Horst Sievert, Ralph L. Sacco, Marco R. Di Tullio · 2016 · Nature Reviews Disease Primers
61. Atrial Fibrillation
    Darae Ko, Mina K. Chung, Peter T. Evans, Emelia J. Benjamin, Robert H. Helm · 2024 · JAMA
62. Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
    Benjamin Adam Steinberg, Peter Shrader, Karen S. Pieper, Laine Elliott Thomas, Larry A. Allen, Jack Ansell, Paul S. Chan, Michael D. Ezekowitz, Gregg C. Fonarow, James V. Freeman et al. · 2018 · Journal of the American Heart Association
63. Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation— Quality and Cost Implications
    Nihar R. Desai, Alexis A. Krumme, Sebastian Schneeweiß, William H. Shrank, Gregory E. Brill, Edmund J. Pezalla, Claire M. Spettell, Troyen A. Brennan, Olga S. Matlin, Jerry Avorn et al. · 2014 · The American Journal of Medicine
64. Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
    Sean D. Pokorney, Jonathan Paul Piccini, Susanna R. Stevens, Manesh R. Patel, Karen S. Pieper, Jonathan L. Halperin, GÜNTER E. BREITHARDT, Daniel E. Singer, Graeme J. Hankey, Werner Hacke et al. · 2016 · Journal of the American Heart Association
65. Trends in Oral Anticoagulant Use Among 436 864 Patients With Atrial Fibrillation in Community Practice, 2011 to 2020
    Ann Marie Návar, Ahmed A. Kolkailah, Robert A. Overton, Nishant P. Shah, Justin F. Rousseau, Greg C. Flaker, Michael Patrick Pignone, Eric David Peterson · 2022 · Journal of the American Heart Association
66. Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms
    Francesco Violi, Elsayed Z. Soliman, Pasquale Pignatelli, Daniele Pastori · 2016 · Journal of the American Heart Association
67. JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
    Takeshi Kitai, Shun Kohsaka, Takao Kato, Eri Toda Kato, Kimi Sato, KANAKO TERAMOTO, Hidenori Yaku, Eiichi Akiyama, Masahiko Ando, Chisato Izumi et al. · 2025 · Circulation Journal
68. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis
    Jonathan A C Sterne, Pritesh N. Bodalia, Peter A. Bryden, Philippa A. Davies, José A López-López, George N. Okoli, Howard H. Z. Thom, Deborah M Caldwell, Sofia Dias, Diane Eaton et al. · 2017 · Health Technology Assessment
69. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial
    Breithardt, Günter, Baumgartner, Helmut, Berkowitz, Scott D., Hellkamp, Anne S., Piccini, Jonathan P., Stevens, Susanna R., Lokhnygina, Yuliya, Patel, Manesh R., Halperin, Jonathan L., Singer, Daniel E. et al. · 2014 · European Heart Journal
70. The State of the Art
    Daniel P. Morin, Michael L. Bernard, Christopher A. Madias, Paul A. Rogers, Sudarone Thihalolipavan, N.A. Mark Estes · 2016 · Mayo Clinic Proceedings
71. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation
    Chern‐En Chiang, Ken Okumura, Shu Zhang, Tze‐Fan Chao, Chung‐Wah Siu, Toon Wei Lim, Anil Saxena, Yoshihide Takahashi, Wee Siong Teo · 2017 · Journal of Arrhythmia
72. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta‐analysis of randomized controlled trials
    Chatree Chai‐Adisaksopha, Christopher Hillis, Tetsuya Isayama, Wendy Lim, Alfonso Iorio, Mark Andrew Crowther · 2015 · Journal of Thrombosis and Haemostasis
73. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management
    Ka Shing Cheung, Wai K. Leung · 2017 · World Journal of Gastroenterology
74. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial
    Jessica L. Mega, Joseph R. Walker, Christian Thomas Ruff, Alexander G. Vandell, Francesco Nordio, Naveen Deenadayalu, Sabina A. Murphy, James Lee, Michele F. Mercuri, Robert Patrick Giugliano et al. · 2015 · The Lancet
75. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics
    Sophie Testa, Armando Tripodi, Cristina Legnani, Vittorio Pengo, Rosanna Abbate, Claudia Dellanoce, Paolo Carraro, Luisa Salomone, Rita Paniccia, Oriana Paoletti et al. · 2015 · Thrombosis Research
76. Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin
    Matthew William Sherwood, Christopher C. Nessel, Anne S. Hellkamp, Kenneth W. Mahaffey, Jonathan Paul Piccini, Eunyoung Suh, Richard Clinton Becker, Daniel E. Singer, Jonathan L. Halperin, Graeme J. Hankey et al. · 2015 · Journal of the American College of Cardiology
77. Early Versus Delayed Non–Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study
    Jonas Oldgren, Signild Åsberg, Ziad Hijazi, Per Olov Wester, Maria Bertilsson, Bo G Norrving, for the National TIMING Collaborators · 2022 · Circulation
78. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation
    Mark S. Link, Robert Patrick Giugliano, Christian Thomas Ruff, Benjamin M. Scirica, H. Huikuri, Ali Oto, Andrea E. Crompton, Sabina A. Murphy, Hans Lanz, Michele F. Mercuri et al. · 2017 · Circulation Arrhythmia and Electrophysiology
79. Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants
    Victoria Allan, Sreeram V Ramagopalan, Jack Mardekian, Aaron K. Jenkins, Xiaoyan Li, Xianying Pan, Xuemei Luo · 2020 · Journal of Comparative Effectiveness Research
80. Adherence to oral anticoagulant therapy in patients with atrial fibrillation
    Valeria Raparelli, Marco Proietti, Roberto Cangemi, Gregory Y.H. Lip, Deirdre A. Lane, Stefania Basili · 2016 · Thrombosis and Haemostasis
81. Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial
    Linda P.T. Joosten, Sander van Doorn, Peter M. van de Ven, B T G Kohlen, Melchior C. Nierman, Huiberdina L. Koek, Martin E W Hemels, Menno Volkert Huisman, Marieke J.H.A. Kruip, Laura M. Faber et al. · 2023 · Circulation
82. Secondary stroke prevention: challenges and solutions
    José Gutierrez, Charles C. Esenwa · 2015 · Vascular Health and Risk Management
83. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time
    Ziad Hijazi, Stefan Hans Hohnloser, Ulrika Andersson, John Hunter Alexander, Michael Hanna, Mátyás Keltai, Alexander N. Parkhomenko, Jose Luis Lopez-Sendon, Renato D. Lópes, Agneta Siegbahn et al. · 2016 · JAMA Cardiology
84. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation
    Surbhi Shah, Faye L. Norby, Yvonne H. Datta, Pamela L. Lutsey, Richard F. MacLehose, Lin Y. Chen, Álvaro Alonso · 2018 · Blood Advances
85. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC
    Anja Katholing, Christopher Wallenhorst, Saul Benedict Freedman, Carlos Martínez · 2015 · Thrombosis and Haemostasis
86. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial
    Claes Held, Elaine M. Hylek, John Hunter Alexander, M. Hanna, Renato D. Lópes, DANIEL M. WOJDYLA, Laine Elliott Thomas, Hussein R. Al‐Khalidi, Marco Alings, Denis Xavier et al. · 2014 · European Heart Journal
87. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub‐Analysis From the PREFER in AF ( PRE vention o F Thromboembolic Events– E uropean R egistry in A trial F ibrillation)
    Giuseppe Patti, Markus Lucerna, Ladislav Pecen, Jolanta Maria Siller-Matula, Ilaria Cavallari, Paulus F. Kirchhof, Raffaele De Caterina · 2017 · Journal of the American Heart Association
88. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes
    Candrika D. Khairani, Antoine Bejjani, Gregory Piazza, David Jiménez, Manuel Monréal, Saurav Chatterjee, Vittorio Pengo, Scott C. Woller, Josefina Cortés-Hernández, Jean M. Connors et al. · 2022 · Journal of the American College of Cardiology
89. Effectiveness and Safety of Non–vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses
    Abdulaali R. Almutairi, Lili Zhou, Walid F. Gellad, Jeannie K. Lee, Marion Kimball Slack, Jennifer R Martin, Wei-Hsuan Lo-Ciganic · 2017 · Clinical Therapeutics
90. Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial
    Ka Sing Wong, Dai Yi Hu, Abraham Oomman, Ru‐San Tan, Manesh R. Patel, Daniel E. Singer, GÜNTER E. BREITHARDT, Kenneth W. Mahaffey, Richard Clinton Becker, Robert M. Califf et al. · 2014 · Stroke
91. Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal
    Gregory Y.H. Lip, Marco Proietti, Tatjana Potpara, MOUSSA C. MANSOUR, Irina Savelieva, Hung‐Fat Tse, Andreas Goette, A. John Camm, Carina Blomström‐Lundqvist, Dhiraj Gupta et al. · 2023 · EP Europace
92. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
    Stefan Hans Hohnloser, A. John Camm, Riccardo Cappato, Hans‐Christoph Diener, Hein Heidbüchel, Lluı́s Mont, Carlos Arturo Morillo, Khalid Abozguia, Massimo Grimaldi, Heiko Rauer et al. · 2019 · European Heart Journal
93. 2024 HRS expert consensus statement on arrhythmias in the athlete: Evaluation, treatment, and return to play
    Lampert, Rachel, Chung, Eugene H., Ackerman, Michael J., Arroyo, Alonso Rafael, Darden, Douglas, Deo, Rajat, Dolan, Joe, Etheridge, Susan P., Gray, Belinda R., Harmon, Kimberly G. et al. · 2024 · Heart Rhythm
94. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling
    Jan Steffel, Robert Patrick Giugliano, Eugene Braunwald, Sabina A. Murphy, Michele F. Mercuri, Youngsook Choi, Philip E. Aylward, Harvey Douglas White, José Luis Zamorano, Elliott Marshall Antman et al. · 2016 · Journal of the American College of Cardiology
95. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves
    Anthony Carnicelli, Raffaele De Caterina, Jonathan L. Halperin, Giulia Renda, Christian Thomas Ruff, Marco Trevisan, Francesco Nordio, Michele F. Mercuri, Elliott Marshall Antman, Robert Patrick Giugliano · 2017 · Circulation
96. Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation
    Yi‐Hsin Chan, Chi-Tai Kuo, Yung‐Hsin Yeh, Shang‐Hung Chang, Lung‐Sheng Wu, Hsin‐Fu Lee, Hui‐Tzu Tu, Lai‐Chu See · 2016 · Journal of the American College of Cardiology
97. Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial
    Chiara Melloni, Allison M. Dunning, Christopher Bull Granger, Laine Elliott Thomas, Michel Georges Khouri, David A. Garcia, Elaine M. Hylek, Michael Hanna, Lars C. Wallentin, Bernard John Gersh et al. · 2017 · The American Journal of Medicine
98. What is ‘valvular’ atrial fibrillation? A reappraisal
    Raffaele De Caterina, A. John Camm · 2014 · European Heart Journal
99. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies
    Apostolos Tzikas, David R. Holmes, Sameer A. Gafoor, Carlos Eduardo Ruiz, Carina Blomström‐Lundqvist, Hans‐Christoph Diener, Riccardo Cappato, Saibal Kar, Randal J. Lee, Robert A. Byrne et al. · 2016 · EuroIntervention
100. Social determinants of atrial fibrillation
     Utibe R. Essien, Jelena Kornej, Amber E. Johnson, Lucy Schulson, Emelia J. Benjamin, Jared W. Magnani · 2021 · Nature Reviews Cardiology